Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY13 · #1.7588359211042812e+16 · 2021
- 피인용
- Web of Science 15Scopus 15
- FWCI (Scopus)
- 0.55
- JCR IF
- JCR 2020 8.168
- ISSN
- 1758-8340
저자
- Han, Hye Sook제1저자Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Internal Med, Coll Med, Cheongju, Chungcheongbuk, South Korea
- Kim, Bum JunHallym Univ, Sacred Heart Hosp, Dept Internal Med, Coll Med, Anyang Si, Gyeonggi Do, South Korea
- Jee, Hee-JungKorea Univ, Coll Med, Dept Biostat, Seoul, South Korea
- Ryu, Min-HeeUniv Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea
- Park, Se HoonSungkyunkwan Univ, Dept Med, Div Hematol Oncol, Samsung Med Ctr, Seoul, South Korea
- Rha, Sun YoungYonsei Univ, Songdang Inst Canc Res, Coll Med, Seoul, South Korea
- Kim, Jong GwangKyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Oncol Hematol, Daegu, South Korea
- Bae, Woo KyunChonnam Natl Univ, Dept Internal Med, Med Sch, Hwasun, Jeollanam Do, South Korea
- Lee, Keun-WookSeoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, South Korea
- Oh, Do-YounSeoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Dept Internal Med,Coll Med, Seoul, South Korea
- Kim, In-HoCatholic Univ Korea, Dept Internal Med, Seoul St Marys Hosp, Seoul, South Korea
- Sym, Sun JinGachon Univ Gil Hosp, Dept Internal Med, Div Hematol & Oncol, Incheon, South Korea
- 오소연Pusan Natl Univ, Dept Internal Med, Yangsan Hosp, Yangsan, South Korea
- Kim, Hyeong SuHallym Univ, Kangnam Sacred Heart Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
- Byun, Ji-HyeHlth Insurance Review & Assessment Serv, Innovat Res Dept, Wonju, South Korea
- Kim, Dong SookHlth Insurance Review & Assessment Serv, Review & Assessment Res Dept, Wonju, South Korea
- Suh, Young JuInha Univ, Coll Med, Dept Biomed Sci, Incheon, South Korea
- An, HyongginKorea Univ, Coll Med, Dept Biostat, Seoul, South Korea
- Zang, Dae Young교신저자Hallym Univ, Dept Internal Med, Hallym Univ Sacred Heart Hosp, Coll Med, 22 Gwanpyeong Ro 170 Beongil Dongan Gu, Anyang Si 14068, Gyeonggi Do, South Korea
초록
Background: Ramucirumab as monotherapy or in combination with paclitaxel is a second-line treatment option recommended for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. However, real-world data from large study cohorts focused on ramucirumab plus paclitaxel in gastric cancer are limited. Methods: The study population comprised all patients with gastric or GEJ cancer who received ramucirumab plus paclitaxel in South Korea between 1 May 2018 and 31 December 2018. We included patients with advanced gastric or GEJ adenocarcinoma and disease progression after first-line platinum and fluoropyrimidine-containing combination chemotherapy. Results: In total, 1063 patients were included in the present study. The objective response rate and disease control rate were 15.1% and 57.7%, respectively. The median progression-free survival was 4.03months (95% confidence interval, 3.80-4.27) and the median overall survival was 10.03months (95% confidence interval, 9.33-10.73). Grade 3 or higher treatment-related adverse events with incidence of 5% were neutropenia (35.1%) and anemia (10.5%). Based on multivariable analysis, overall survival was negatively associated with Eastern Cooperative Oncology Group performance status 2, weight loss 10% in the previous 3months, GEJ of primary tumor, poor or unknown histologic grade, number of metastatic sites 3, presence of peritoneal metastasis, no prior gastrectomy, and time to second-line since first-line treatment <6months. Conclusion: Our large-scale, nationwide, real-world data analysis of an unselected real-world population adds evidence for the efficacy and safety of second-line ramucirumab plus paclitaxel in patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
키워드
gastric cancerpaclitaxelramucirumabreal-world dataRANDOMIZED CLINICAL-TRIALPHASE-III1ST-LINE THERAPYDOUBLE-BLINDOPEN-LABELCANCERCHEMOTHERAPYRAINBOWCOMBINATIONEAST
식별자
- Scopus EID
- 2-s2.0-85115063816
- WoS UID
- 000697412800001



로그인
연구물 목록으로